BRCA2 and bone neoplasm: BRCA2 mutation increased pharyngeal cancer (RR 7.30 [1.66–32.01]), oesophageal cancer (RR 4.1 [1.26–13.3]), hepatic cancer (RR 3.59 [1.04–12.34]), gallbladder and biliary cancers (RR 4.7 [1.42–15.53]), endometrial cancer (RR 6.2 [2.33–16.52]), uveal melanoma (99.4 [15.69–629.85]) or bone cancer (RR 6.76 [1.09–42.07]) but did not increase cancers of the tongue or salivary glands or the small intestines.